Table 2

Association between CYP1B1 genotype and breast cancer risk by histological subtype and receptor status

Val/Val (ml)an (%)Val/Leu+ Leu/Leu n (%)OR (95% CI)Adjusted OR (95% CI)Asn/Asn (m2)aAsn/Ser+ Ser/SerOR (95% CI)Adjusted OR (95% CI)
Controls91 (20)365 (80)1.0b1.0c300 (66)156 (34)1.0b1.0c
Cases
Invasive cases only78 (21)300 (79)0.95 (0.68–1.33)1.0 (0.71–1.45)266 (70)112 (30)0.81 (0.60–1.09)0.82 (0.60–1.11)
Involved nodes
 ≥122 (21)82 (79)0.90 (0.53–1.54)0.92 (0.53–1.62)74 (71)30 (29)0.76 (0.47–1.22)0.76 (0.46–1.25)
 ≥410 (28)26 (72)0.69 (0.32–1.51)0.74 (0.32–1.70)28 (78)8 (22)0.53 (0.23–1.20)0.57 (0.24–1.33)
Receptor status
 ER+59 (24)185 (76)0.75 (0.51–1.09)0.76 (0.51–1.12)169 (69)75 (31)0.83 (0.60–1.17)0.84 (0.59–1.20)
 ER−6 (10)50 (89)2.26 (0.93–5.49)2.35 (0.94–5.89)41 (73)15 (27)0.73 (0.39–1.37)0.74 (0.38–1.43)
 PR+34 (19)148 (81)1.10 (0.69–1.67)1.04 (0.65–1.65)124 (68)58 (32)0.88 (0.61–1.28)0.87 (0.59–1.28)
 PR−27 (25)80 (75)0.74 (0.45–1.23)0.81 (0.48–1.37)78 (73)29 (27)0.70 (0.44–1.13)0.70 (0.42–1.15)
  • a Reference categories.

  • b Unconditional logistic regression adjusted for the matching variables: age, menopausal status, postmenopausal status, postmenopausal hormone use, data at blood draw, time at blood draw, and fasting status.

  • c Unconditional logistic regression adjusted for the matching variables and age at menarche, parity, age at first birth, BMI at age 18, weight gain since age 18, benign breast disease, first-degree family history of breast cancer, and duration of postmenopausal hormone use.

  • d PR, progesterone receptor.